Sezai Arslan | Inherited Metabolic Disorders | Innovative Research Award

Innovative Research Award

Sezai Arslan – Erzurum City Hospital, Turkey

Sezai Arslan
Affiliation Erzurum City Hospital
Country Turkey
Scopus ID 58087780600
Documents 7
Citations 21
h-index 2
Subject Area Inherited Metabolic Disorders
Event International Research Data Analysis Excellence & Awards
ORCID 0000-0002-3873-3010

The Innovative Research Award recognizes the academic and clinical research profile of Sezai Arslan, affiliated with Erzurum City Hospital in Turkey. The profile is associated with research in inherited metabolic disorders and is represented through scholarly identifiers, publication records, citation indicators, and professional research links. [1]

Abstract

Sezai Arslan is associated with clinical and academic research concerning inherited metabolic disorders. The available scholarly profile records seven documents, twenty-one citations, and an h-index of two. These indicators provide a concise representation of documented publication activity and research visibility relevant to academic recognition.[2]

Keywords

Innovative Research Award; Sezai Arslan; Erzurum City Hospital; inherited metabolic disorders; clinical research; scholarly publications; Scopus; ORCID; research impact; academic recognition.

Introduction

Research in inherited metabolic disorders contributes to improved understanding of rare conditions, diagnostic pathways, and clinical management. Sezai Arslan’s scholarly profile reflects participation in this specialized field through documented publications and citation activity. Academic identifiers support transparent recognition of research outputs and professional contributions. [3]

Research Profile

Sezai Arslan is affiliated with Erzurum City Hospital in Turkey and is associated with research in inherited metabolic disorders. The available Scopus author record identifies seven indexed documents, twenty-one citations, and an h-index of two. ORCID provides an additional persistent identifier supporting researcher identification. [1]

Research Contributions

The documented research activity is situated within inherited metabolic disorders, an area requiring clinical knowledge and systematic scientific investigation. Publications associated with the researcher contribute to the accessible scholarly record. Such contributions may support continuing discussion of disease characteristics, diagnostic approaches, and evidence-based clinical research. [2]

Publications

The available Scopus profile records seven documents attributed to the researcher. Indexed publications provide a measurable record of scholarly activity and enable evaluation through bibliographic databases. Publication information, citation relationships, journal metadata, and relevant digital identifiers collectively support verification and long-term accessibility of academic outputs. [1]

Research Impact

Available bibliometric indicators show twenty-one citations and an h-index of two. These measures offer a limited quantitative perspective on the visibility of indexed publications and their use within subsequent scholarly work. Research impact should also be interpreted alongside subject specialization, clinical relevance, publication quality, and broader professional context. [3]

Award Suitability

The available profile demonstrates documented research activity, identifiable scholarly outputs, and a specialized subject focus. These characteristics provide relevant evidence for consideration under an Innovative Research Award framework. Final suitability remains dependent on formal eligibility criteria, independent review procedures, originality, research quality, and comparison with other eligible candidates.[3]

Conclusion

Sezai Arslan’s available academic profile reflects research involvement in inherited metabolic disorders through seven indexed documents and measurable citation activity. Persistent researcher identifiers enhance profile transparency and verification. The documented record provides a factual basis for academic recognition while emphasizing the importance of comprehensive peer review and formal award evaluation. [2]

References

  1. Carnitine, Amino Acids, Vitamins, and Hematological Status in Children with Classical Phenylketonuria: A Case–Control Study.
    https://www.mdpi.com/2072-6643/18/15/2407
  2. Genetic insights and biochemical profiles in hyperlipidemia: a cohort study from Eastern Anatolia.
    https://www.researchgate.net/publication/394102170_Genetic_insights_and_biochemical_profiles_in_hyperlipidemia_a_cohort_study_from_Eastern_Anatolia
  3. Genotype–Phenotype Correlations in Phenylketonuria and Hyperphenylalaninemia: A Single-Center Study.
    https://onlinelibrary.wiley.com/doi/abs/10.1111/ped.70441

Lakshminarayan Ranganath | Metabolic Medicine | Best Researcher Award

Prof Dr. Lakshminarayan Ranganath | Metabolic Medicine | Best Researcher Award

Prof Dr. Lakshminarayan Ranganath at University of Liverpool/Royal Liverpool University Hospital, United Kingdom

👨‍🎓 Profiles

👨‍⚕️ Academic background

Professor Lakshminarayan Ranganath is a distinguished British Indian medical professional, currently serving as a Professor in Clinical Chemistry at the University of Liverpool. He is also a Consultant Chemical Pathologist at Royal Liverpool University Hospital and holds multiple prestigious roles including Clinical Director of the National Alkaptonuria Centre and Chief Investigator of the DevelopAKUre Project. He can be reached at his work address: Department of Clinical Biochemistry and Metabolic Medicine, Liverpool University Hospitals, Prescot Street, Liverpool, UK, L7 8XP. For any queries, he is available on his work phone at ++44 (0151 706 4289), home phone at ++44 (0151 280 6459), and mobile at ++44 (07842849520). His preferred email for university correspondence is lrang@liv.ac.uk.

🎓 Professional and Academic Qualifications

Professor Ranganath’s academic journey is marked by extensive qualifications. He completed his MBBS and MD in General Medicine from the University of Madras, India. He furthered his education with an MSc in Clinical Biochemistry from the University of Surrey, UK, followed by MRCP in General Medicine and MRCPath in Chemical Pathology from the Royal College of Physicians and Royal College of Pathologists, respectively. He achieved his PhD from the University of Surrey and received Fellowships from the Royal College of Pathologists and the Royal College of Physicians of Edinburgh. His credentials also include CSci from the Association of Clinical Biochemistry UK, and he is listed with the European Association of Clinical Chemistry and the European Register of Specialists in Laboratory Medicine.

🏆 Awards and Honors

Throughout his career, Professor Ranganath has been recognized with numerous awards. In India, he received the UNC Rao Gold Medal for Anatomy and the T Sundara Reddy Memorial Prize. In the UK, he has been honored with the RARE Champion of Hope Medical Care and Treatment Award, the Golan and Christie Patient Impact Philanthropy Award, the Honorary Association of Clinical Biochemistry Membership Award, and the Association of Clinical Biochemistry and Laboratory Medicine Inaugural Impact Award.

🔬 Professional Contributions

Professor Ranganath has made significant contributions to the field of medical science. He has served on advisory boards for major pharmaceutical companies like Pfizer and Sobi, and has been an invited Guest Editor for the Journal of Inherited Metabolic Diseases. He has held roles such as Specialty Adviser on Chemical Pathology at the Royal College of Pathologists and Examiner in Clinical Biochemistry. He has also been involved in various scientific and organizing committees.

🧬 Alkaptonuria Research

A major focus of Professor Ranganath’s research is alkaptonuria (AKU). He co-founded the UK AKU Society and has been instrumental in establishing a dedicated research team. His work led to the successful coordination of the DevelopAKUre Project, which was pivotal in securing European Medicines Agency approval for nitisinone as a disease-modifying therapy for AKU. He is also engaged in developing novel treatments for AKU and has celebrated significant milestones like the 10-year anniversary of the National Alkaptonuria Centre in Liverpool.

📚 Non-Alkaptonuria Research

In addition to his work on alkaptonuria, Professor Ranganath has conducted pioneering research in incretin biology, particularly glucagon-like peptide 1 (GLP-1). His PhD studies were groundbreaking in identifying GLP-1 deficiency in obesity. He has authored several publications on GLP-1 and has mentored PhD students in this area.

🔍 Current Clinical Research

Currently, Professor Ranganath is leading various clinical research projects. As Principal Investigator, he is overseeing studies such as the Zolendronate Infusion in Prevention of Paget’s Study (ZIPP) and research on alkaptonuria. He is also collaborating on repurposing nitisinone for malaria and conducting follow-up studies on the outcomes of nitisinone therapy in AKU patients.

👨‍🎓 Research Students Supervised

Professor Ranganath has supervised numerous PhD students, focusing on topics like AKU, GLP-1, and biochemical studies. His mentorship has supported a diverse range of research projects, contributing significantly to advancements in these fields.

💰 Research Funding

Professor Ranganath has secured substantial funding for his research, including grants from the National Lottery, Childwick Trust, and European sources. His research efforts, particularly in alkaptonuria, have attracted over £10 million in funding, demonstrating the significant impact of his work.

📖 Books and Book Chapters

Professor Ranganath has authored and contributed to several influential books and book chapters. His works include contributions to texts on biochemistry, metabolism, and alkaptonuria, reflecting his extensive expertise and impact on these subjects.

📖 Publications

Joint replacement risk is markedly increased in alkaptonuria (AKU) in those with prior arthroplasty
    • Authors: Ranganath, L.R., Khedr, M., Norman, B.P., Gallagher, J.A., Bou-Gharios, G.
    • Journal: Molecular Genetics and Metabolism Reports
    • Year: 2024
Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria
    • Authors: Norman, B.P., Sutherland, H., Wilson, P.J.M., Bou-Gharios, G., Ranganath, L.R.
    • Journal: Journal of Inherited Metabolic Disease
    • Year: 2024
Correction to: Analysis of the Phenotype Differences in Siblings with Alkaptonuria (Metabolites, (2022), 12, 10, (990), 10.3390/metabo12100990)
    • Authors: Zatkova, A., Olsson, B., Ranganath, L.R., Imrich, R.
    • Journal: Metabolites
    • Year: 2024
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone
    • Authors: Phillips, J., Subedi, D., Lewis, S.C., Gilchrist, N., Ralston, S.H.
    • Journal: Annals of the Rheumatic Diseases
    • Year: 2023
Clinical development innovation in rare diseases: overcoming barriers to successful delivery of a randomised clinical trial in alkaptonuria—a mini-review
    • Authors: Ranganath, L.R., Sireau, N.
    • Journal: Orphanet Journal of Rare Diseases
    • Year: 2023
Clinical presentation of 13 children with alkaptonuria
    • Authors: Kujawa, M.J., Świętoń, D., Wierzba, J., Ranganath, L., Piskunowicz, M.
    • Journal: Journal of Inherited Metabolic Disease
    • Year: 2023
Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
    • Authors: Genovese, F., Frederiksen, P., Bay-Jensen, A.-C., Gallagher, J.A., Ranganath, L.R.
    • Journal: International Journal of Molecular Sciences
    • Year: 2023
Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial
    • Authors: Ooi, N., Cooper, I.R., Norman, B., Ranganath, L.R., Savage, V.J.
    • Journal: Cells
    • Year: 2023
First decade anniversary of the United Kingdom National Alkaptonuria Centre
    • Authors: Khedr, M., Sireau, N., Bou-Gharios, G., Gallagher, J.A., Ranganath, L.R.
    • Journal: JIMD Reports
    • Year: 2023